Statin Benefit Calculator: Estimating Absolute Risk Reduction, NNT, and LDL Lowering

The decision to start a statin is one of the most common and most consequential conversations in preventive cardiology. Statins lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of heart attack, ischemic stroke, and cardiovascular death. What varies enormously from one person to another is how much benefit a statin actually delivers, how long it takes to accrue, and how that benefit compares with the small but real risk of side effects. A Statin Benefit Calculator translates a patient’s baseline cardiovascular risk into concrete, personalized numbers: absolute risk reduction, relative risk reduction, number needed to treat, and the projected drop in LDL-C with a specific statin intensity. This page explains the clinical science, the formulas, and how to interpret the results in the context of shared decision making.

What This Calculator Does and Who It Is For

This tool is designed for clinicians, students, and engaged patients who want to quantify the expected benefit of statin therapy for a specific individual. It takes four inputs: the patient’s baseline 10-year risk of atherosclerotic cardiovascular disease (ASCVD), their current LDL-C level, the chosen statin intensity, and the time horizon over which to project benefit. From these, it estimates the relative risk reduction, the absolute risk reduction, the number needed to treat, and the projected on-treatment LDL-C. The calculator does not replace formal risk scoring tools such as the Pooled Cohort Equations, SCORE2, QRISK3, or the PREVENT equations. Instead, it starts where those tools finish, turning a single risk percentage into a personalized picture of what statin therapy is likely to do for that person.

The calculator is most useful in three scenarios. The first is primary prevention decision making, where a patient at intermediate risk is weighing the benefits and burdens of daily medication. The second is intensity selection, where a clinician wants to compare the expected outcomes of moderate versus high-intensity therapy for a high-risk patient. The third is patient education, where abstract percentages become tangible numbers that support shared decision making.

The Evidence Base Behind the Numbers

The mathematics of statin benefit is built on one of the largest and most consistent bodies of evidence in modern medicine. The Cholesterol Treatment Trialists’ Collaboration has repeatedly pooled individual participant data from the major statin randomized controlled trials. Their landmark 2010 meta-analysis of 26 trials covering 170,000 participants established the 22 percent relative risk reduction per 1 mmol/L LDL-C reduction figure. Subsequent analyses in specific subgroups, including older adults, women, patients with diabetes, and those with chronic kidney disease, have confirmed that the relationship holds across populations with remarkable consistency.

The linearity of the LDL-benefit relationship is what makes the calculator possible. Each additional mmol/L reduction delivers approximately the same proportional benefit, whether the LDL-C starts at 5 mmol/L and drops to 4, or starts at 3 mmol/L and drops to 2. This has been confirmed down to LDL-C values well below 1 mmol/L in trials using statins combined with ezetimibe or PCSK9 inhibitors. The principle of lower is better, down to very low LDL-C levels, underpins modern lipid guidelines from the American Heart Association, the European Society of Cardiology, and national bodies worldwide.

Understanding Baseline Cardiovascular Risk

Baseline 10-year ASCVD risk is the probability that a person will experience a major cardiovascular event over the next decade if no lipid-lowering treatment is initiated. This is the essential input for any benefit calculation, because the absolute benefit of any preventive therapy scales directly with baseline risk. A statin that produces a 25 percent relative risk reduction is worth very different things to a 30-year-old with a 2 percent 10-year risk and a 70-year-old with a 30 percent 10-year risk.

Several validated risk calculators are in widespread use. The Pooled Cohort Equations were developed from four US cohorts and remain the standard in North American practice. SCORE2 and SCORE2-OP serve European populations across four risk regions. QRISK3 is used in the United Kingdom and captures additional variables such as chronic kidney disease and atypical antipsychotic use. The PREVENT equations, released in 2023, update the US approach by incorporating kidney function and metabolic factors while removing race as a variable. For secondary prevention, 10-year risk is no longer strictly estimated from an equation, because recurrent event rates are routinely 20 percent or higher and a statin is almost always indicated regardless.

How Statin Intensity Translates Into LDL Reduction

The AHA/ACC classification divides statins into three intensity categories based on the average percentage reduction in LDL-C. Low-intensity statins reduce LDL-C by less than 30 percent on average. This category includes simvastatin 10 mg, pravastatin 10 to 20 mg, lovastatin 20 mg, fluvastatin 20 to 40 mg, and pitavastatin 1 mg. Low-intensity therapy is rarely chosen as first-line treatment in current guidelines, but it may be appropriate for patients with a history of severe statin intolerance or those with very low baseline risk.

Moderate-intensity statins reduce LDL-C by 30 to 49 percent on average. Common regimens include atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, pravastatin 40 to 80 mg, lovastatin 40 mg, fluvastatin 80 mg, and pitavastatin 2 to 4 mg. Moderate intensity is the default recommendation for most patients with intermediate cardiovascular risk and for those over 75 starting statin therapy for primary prevention.

High-intensity statins reduce LDL-C by 50 percent or more on average. Only two regimens reliably achieve this: atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg. High intensity is the standard of care for secondary prevention (patients with established atherosclerotic disease), for primary prevention in patients with LDL-C above 4.9 mmol/L (190 mg/dL), for diabetes with additional risk factors, and for primary prevention in those at high 10-year risk where intensive lowering is expected to yield meaningful absolute benefit.

The Formula Explained Step by Step

The calculator applies a four-step model. First, it converts baseline LDL-C into the canonical unit of mmol/L if the user enters mg/dL (mg/dL divided by 38.67 equals mmol/L). Second, it computes the projected on-treatment LDL-C by applying the intensity-specific percent reduction, yielding delta LDL in mmol/L. Third, it applies the CTT exponential formula, RRR equals 1 minus exp of negative 0.22 times delta LDL, to obtain the relative risk reduction over five years. For longer or shorter time horizons, benefit is scaled proportionally, with explicit recognition that treatment benefit accumulates over time.

Fourth, the calculator multiplies baseline 10-year risk by the time-horizon scaled RRR to obtain absolute risk reduction, then inverts ARR to produce NNT. The result is a small set of clinically interpretable numbers. A patient with a 15 percent 10-year ASCVD risk, LDL-C of 4.0 mmol/L, starting atorvastatin 40 mg (high intensity, assumed 50 percent LDL reduction) would achieve a delta LDL of 2.0 mmol/L. The RRR over five years is 1 minus exp of negative 0.44, approximately 35.6 percent. Scaled to ten years, this yields an ARR around 5.3 percent and an NNT of 19, meaning roughly 19 such patients must take high-intensity statin for ten years to prevent one major cardiovascular event.

Interpreting Number Needed to Treat in Practice

NNT is a powerful clinical communication tool, but it requires careful interpretation. A smaller NNT means greater benefit per person treated. Published NNT figures for statin therapy in secondary prevention over five years are typically in the range of 25 to 40. For high-risk primary prevention over ten years, NNTs often fall in the 20 to 50 range. For low-risk primary prevention, NNT can exceed 100, which prompts careful weighing of treatment burden against expected gain.

NNT must always be paired with the time horizon. An NNT of 40 over five years is very different from an NNT of 40 over one year. A common mistake is to compare NNTs from trials of different durations as if they were equivalent. The calculator on this page always reports NNT alongside the time horizon used in the projection, and it allows users to explore how extending the horizon from five to ten or fifteen years changes the picture.

Time Horizon and the Cumulative Nature of Benefit

Statin benefits are not delivered all at once. Clinical trials show that a small but measurable reduction in cardiovascular events emerges within the first year, grows steadily through years two to five, and continues to accumulate for as long as therapy is maintained. This cumulative pattern has important implications. A patient who stops statin therapy after one year loses most of the potential long-term benefit. A patient who maintains therapy for decades continues to accrue reduced risk, with follow-up data from trials such as West of Scotland Coronary Prevention Study showing persistent benefit 20 years after the original trial ended.

The calculator allows users to project over one, five, ten, or fifteen year horizons. A useful rule of thumb is that NNT over ten years is roughly half the NNT over five years, although this approximation breaks down for very long horizons where competing mortality becomes important. For patients over 75 starting primary prevention, competing risk from other causes of death materially limits the expected benefit, which is why recent guidelines emphasize shared decision making and consideration of life expectancy in this age group.

When the Calculator Applies and When It Does Not

This calculator is designed for adults aged 40 to 75 who do not have established cardiovascular disease and who are being considered for primary prevention with a statin. It performs reasonably for adults up to age 85 in secondary prevention settings, but the underlying CTT data include fewer participants in very old age and very young adulthood. For patients under 40, the Pooled Cohort Equations and similar tools substantially underestimate lifetime risk, and lifetime benefit calculations require different models that are beyond the scope of this tool.

The calculator also does not apply to patients with familial hypercholesterolemia, where LDL-C levels above 4.9 mmol/L (190 mg/dL) indicate a lifetime burden of atherosclerosis that standard 10-year risk scores do not capture. In this group, statin therapy is indicated on the basis of LDL-C alone, typically at high intensity, often combined with ezetimibe or PCSK9 inhibitors. For pregnant or breastfeeding women, statins are contraindicated, and the calculator is not applicable.

Balancing Benefits Against Adverse Effects

Any benefit calculation must be considered alongside the risks and burdens of therapy. Statins have an excellent safety profile relative to most medications, but they are not risk-free. Statin-associated muscle symptoms are the most common reason for discontinuation, affecting roughly 5 to 10 percent of users in observational studies, though the figure in placebo-controlled trials is much lower (around 1 to 2 percent attributable to the drug itself). A small incremental risk of new-onset type 2 diabetes has been consistently observed, on the order of one excess case per 250 patient-years of treatment. Rhabdomyolysis is rare, with an incidence of less than 1 per 10,000 patient-years.

For most patients at intermediate or high risk, the cardiovascular benefits substantially outweigh these risks. For low-risk patients, the balance is closer, and the calculator helps make that trade-off explicit. The absolute magnitude of benefit, expressed as events prevented per 100 patients over the time horizon, can be directly compared with the absolute magnitude of expected adverse effects. When presented this way, most patients are able to reach an informed decision that reflects their own values and preferences.

Combining Statins With Other Lipid-Lowering Therapies

The calculator models statin monotherapy, but many patients require combination therapy to reach LDL-C targets. Ezetimibe, when added to a statin, typically lowers LDL-C by an additional 15 to 25 percent. PCSK9 inhibitors (evolocumab and alirocumab) add another 50 to 60 percent reduction on top of statin therapy. Bempedoic acid, inclisiran, and dietary modification provide further incremental reductions. Each additional mmol/L reduction in LDL-C is expected to yield a further 22 percent relative risk reduction, per the CTT framework. Users who want to model combination therapy can manually adjust the statin intensity input to reflect the total expected LDL-C reduction from their full regimen.

Unit Conversions and Global Reporting Conventions

LDL-C is reported in mmol/L in most of Europe, the United Kingdom, Canada, Australia, and much of Asia. It is reported in mg/dL in the United States and several other regions. The conversion is straightforward: mg/dL divided by 38.67 equals mmol/L, and mmol/L multiplied by 38.67 equals mg/dL. Common clinical thresholds translate as follows: 2.0 mmol/L is approximately 77 mg/dL, 2.6 mmol/L is approximately 100 mg/dL, 3.4 mmol/L is approximately 130 mg/dL, 4.1 mmol/L is approximately 160 mg/dL, and 4.9 mmol/L is approximately 190 mg/dL. The calculator accepts either unit and normalizes internally.

Shared Decision Making With the Results

Clinical guidelines increasingly emphasize shared decision making for statin therapy, particularly in primary prevention. The calculator output can structure this conversation. A productive format is to present three numbers to the patient: the baseline 10-year risk (for example, 12 percent), the projected 10-year risk on statin therapy (for example, 8.4 percent), and the NNT over ten years (for example, 28). This makes clear that three or four patients out of 100 will avoid a major cardiovascular event, while the remaining patients either would not have had an event anyway or still experience one despite treatment.

Layering in patient preferences and values is the final step. Some patients are strongly averse to taking daily medication and will choose statin only if the NNT is low. Others have witnessed cardiovascular disease in family and are willing to accept a higher NNT for any meaningful reduction. Either position can be defensible, and the calculator supports the conversation without dictating a conclusion.

Limitations of This Calculator

Several important limitations should be understood before applying the results clinically. First, the CTT 22 percent per mmol/L figure is an average across many populations and many events. Individual patients may derive somewhat more or less benefit depending on factors not captured in 10-year risk scores, including inflammatory markers, coronary artery calcium score, family history patterns, and genetic risk. Second, the calculator does not model compound effects of improved lifestyle, blood pressure control, or antiplatelet therapy, each of which can further reduce residual risk.

Third, the calculator assumes good adherence. Real-world adherence to statins is imperfect, with studies showing that 30 to 50 percent of patients discontinue within the first year. Non-adherence proportionally reduces the real-world benefit. Fourth, the time-scaling approach is a simplification. Event rates within the first year on statin therapy are lower than a strict linear extrapolation would predict, and long-term follow-up studies show benefit continuing to grow beyond the trial period. The calculator errs on the side of being conservative in its estimates.

Frequently Asked Questions

Conclusion

Statin therapy is one of the best-studied and most effective interventions in all of medicine, yet the decision to start a statin for any given individual requires a careful translation of population-level trial results into personal context. The Statin Benefit Calculator on this page performs that translation. It converts a baseline 10-year cardiovascular risk and an LDL-C measurement into four clinically meaningful numbers: relative risk reduction, absolute risk reduction, number needed to treat, and projected on-treatment LDL-C. The mathematics rests on the exponential risk reduction model derived from the Cholesterol Treatment Trialists’ Collaboration, the most comprehensive body of evidence on lipid lowering and cardiovascular outcomes ever assembled. The calculator is a decision aid, not a replacement for clinical judgment, patient preference, and ongoing monitoring. Used thoughtfully in the context of shared decision making, it helps clinicians and patients reach statin decisions that reflect both the best available evidence and the values of the person at the center of the conversation.